Every promising male contraceptive target deserves the support necessary to determine whether or not it is a next generation birth control method.
Contraceptive Accelerator Network (CAN) is a small mission-centric pharmaceutical company created with the specific intent of ensuring that promising non-hormonal, reversible contraceptive targets receive the support necessary to develop them as next generation birth control methods delivered to those who produce sperm.
|
The Contraceptive Accelerator Network, LLC is a for-profit subsidiary of MCI with $1.0M in private investment. It works in parallel with MCI to identify appropriate programs and support them with the testing and evaluation processes required prior to Investigational New Drug (IND)-enabling studies and clinical trials.
The company’s operations are streamlined and intentionally designed to maximize cost efficiency in all activities, taking advantage of the many drug discovery resources commercially available to increase our impact while reducing overhead costs and allowing for an expanded portfolio of projects as and when appropriate. |
|
MCI’s granting and investment activities sufficiently de-risk early stage targets such that CAN is able to identify the most salient options and work through a collaborative network of researchers, advisers, and other external resources to accelerate the development of new sperm-targeting contraceptives in an effort to expeditiously facilitate their market-readiness. Projects held by CAN are given individualized attention, and progressed in a way that advances the program into clinical trials, de-risks future studies, and incentivizes follow-on investment.
CAN is structured such that any profits generated from the contraceptive products it develops are reinvested in MCI. This innovative structure disrupts the traditional model of contraceptive drug development in a multitude of ways:
CAN is structured such that any profits generated from the contraceptive products it develops are reinvested in MCI. This innovative structure disrupts the traditional model of contraceptive drug development in a multitude of ways:
- It ensures the continued support of early stage research and development activities and maturation into active contraceptive development programs
- It allows for the potential expanded support of the male contraceptive R&D field with a prospective infusion of additional capital
- It provides the MCI/CAN cohort more control over the cost of the products it develops once they are market-ready, which by extension can help ensure greater access domestically and internationally
- It prevents promising male contraceptive leads from being shelved due to a lack of meaningful development support
- It acts as an incubator, and facilitates the growth of a program while actively looking for mission-driven partners interested in technology transfer and product development
- It values transparency and partnerships, bringing the values of philanthropy into pharmaceutical development
Male Contraceptive Initiative & Contraceptive Accelerator Network's System Map
